Cointime

BridgeBio Pharma

company

About

BridgeBio Pharma focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D.

  • 251 - 500

Highlights

Total Funding Amount
$474.20M
Funding Rounds
4
Investors
4

Details

Last Funding Type
Series D
Last Funding Money Raised
$299.20M
Industries
Biotechnology,Health Care,Life Science,Medical,Pharmaceutical
Founded date
Jan 1, 2014
Number Of Employee
251 - 500
Operating Status
Active

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.

BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$474.20M
BridgeBio Pharma has raised a total of $474.20M in funding over 2 rounds. Their latest funding was raised on Jan 23, 2019 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 23, 2019 Series D $299.20M 3 Kohlberg Kravis Roberts — Detail
Sep 13, 2017 Series C $135M 2 Kohlberg Kravis Roberts — Detail
May 1, 2017 Series B $33.10M 1 Kohlberg Kravis Roberts — Detail
Mar 1, 2016 Series B $6.90M 1 Kohlberg Kravis Roberts — Detail

Investors

Number of Lead Investors
Number of Investors
4
4
BridgeBio Pharma is funded by 4 investors. Kohlberg Kravis Roberts and Sequoia Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Kohlberg Kravis Roberts Yes Series D
Sequoia Capital — Series D
Hercules Capital — Series D
Janus Fund — Series C
Cointime
เนื้อหา
บริษัท